Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers (COACT-2)

A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With an Infected Foot Ulcer

This is a phase 3, randomized, controlled, blinded, multicenter study conducted in 3 parallel cohorts of diabetic patients with at least 1 infected foot ulcer. Patients will be randomized to receive 1 of 3 study treatments; systemic antibiotic therapy and standard ulcer care with either (A) daily application of a gentamicin-sponge, (B) daily application of a placebo-sponge or (C) no-sponge, in the ratio 2:1:1. Patients will be treated for approximately 28 days and return to the clinic weekly for safety and efficacy assessments. After completing treatment, patients will return to the clinic for scheduled follow-up visits approximately 10, 30, 60 and 90 days after treatment is stopped.

Study Overview

• Status: Completed
• Conditions: Infection; Foot Ulcer, Diabetic
• Intervention / Treatment: Drug: Gentamicin Collagen sponge; Other: Placebo

Detailed Description

This is a phase 3, randomized, controlled, blinded, multicenter study conducted in 3 parallel cohorts of diabetic patients with at least 1 infected foot ulcer. Patients will be randomized using an electronic randomization system to receive 1 of 3 study treatments; systemic antibiotic therapy and standard ulcer care with either (A) daily application of a gentamicin-sponge, (B) daily application of a placebo-sponge or (C) no-sponge, in the ratio 2:1:1. The investigator will be blinded to the patient's treatment group assignment and patients randomized to one of the 2 sponge groups will be blinded as to whether the sponge is active or placebo.

If a patient has multiple infected ulcers, the assigned treatment will be administered to all infected ulcers. The investigator will determine the highest severity ulcer to be used for all efficacy evaluations and will also determine the size and number of sponges (up to 4) that a patient will use in order to completely cover all infected ulcers. The investigator will prescribe an empiric systemic antibiotic therapy based on protocol instructions.

Patients will be treated for approximately 28 days and return to the clinic weekly for safety and efficacy assessments. The investigator will stop study treatment if a patient achieves clinical cure by or after the 3rd treatment visit (approximately study day 15). After completing treatment, patients will return to the clinic for scheduled follow-up visits or until ulcer closure. The final efficacy assessments used in the primary efficacy analyses will be obtained at the first follow-up visit approximately 10 days after treatment is stopped. The remaining follow-up visits will occur at approximately 30, 60 and 90 days after treatment is stopped when patients will be assessed for ulcer closure and any re-infection.

• Study Type: Interventional
• Enrollment (Actual): 524
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Cowra, New South Wales, Australia, 2794
  • Queensland
    • Spring Hill, Queensland, Australia, 4006
• Austria
  • Vienna, Austria, 1030
  • Vienna, Austria, 1130
  • Styria
    • Graz, Styria, Austria, 8036
• Belgium
  • Brussels, Belgium, 1090
  • Edegem, Belgium, 2650
  • Kortrijk, Belgium, 8500
  • Liége, Belgium, 4000
  • Pellenberg, Belgium, 3212
• Czechia
  • Brno, Czechia, 656 91
  • Pardubice, Czechia, 532 03
  • Praha 10, Czechia, 100 34
  • Praha 2, Czechia, 128 08
  • Praha 4, Czechia, 140 59
  • Praha 6, Czechia, 169 02
  • Třinec, Czechia, 739 61
  • Zlín, Czechia, 760 01
• Denmark
  • Hillerød, Denmark, 3400
  • København, Denmark, 2400
• Germany
  • Berlin, Germany, 10787
  • Baden-Württemberg
    • Bad Mergentheim, Baden-Württemberg, Germany, 97980
  • Bayern
    • Aschaffenburg, Bayern, Germany, 63739
  • Hessen
    • Fulda, Hessen, Germany, 36037
  • Nordrhein-Westfalen
    • Dortmund, Nordrhein-Westfalen, Germany, 44137
    • Duisburg, Nordrhein-Westfalen, Germany, 47051
    • Münster, Nordrhein-Westfalen, Germany, 48145
  • Reinland-Pfalz
    • Bosenheim, Reinland-Pfalz, Germany, 55545
  • Sachsen
    • Dresden, Sachsen, Germany, 01279
    • Pirna, Sachsen, Germany, 01796
• Hungary
  • Debrecen, Hungary, 4032
  • Hatvan, Hungary, 3000
  • Orosháza, Hungary, 5900
  • Szekszárd, Hungary, 7100
  • Székesfehérvár, Hungary, 8000
  • Sátoraljaújhely, Hungary, 3980
• Ireland
  • Waterford, Ireland
• Italy
  • CB
    • Campobasso, CB, Italy, 86100
  • PD
    • Abano Terme, PD, Italy, 35031
  • PV
    • Pavia, PV, Italy, 27100
  • Point
    • Pistoia, Point, Italy, 51100
  • VI
    • Bassano del Grappa, VI, Italy, 36061
• Netherlands
  • Almere, Netherlands, 1315RA
  • Eindhoven, Netherlands, 5631BM
  • Maastricht, Netherlands, 6229 HX
  • Nijmegen, Netherlands, 6525 GA
  • Nijmegen, Netherlands, 6532 SZ
  • Utrecht, Netherlands, 3582KE
  • the Hague, Netherlands, 2526HW
• Poland
  • Chorzow, Poland, 41-400
  • Czestochowa, Poland, 42-202
  • Gdańsk, Poland, 80-952
  • Krakow, Poland, 30-347
  • Lodz, Poland, 90-553
  • Lublin, Poland, 20-081
  • Poznań, Poland, 616-111
  • Studzionka, Poland, 43-245
  • Warszawa, Poland, 02-541
  • Zabrze, Poland, 41-819
  • Lower Silesia
    • Wrocław, Lower Silesia, Poland, 51-124
• Slovakia
  • Bratislava, Slovakia, 81369
  • Bratislava, Slovakia, 83103
  • Nitra, Slovakia, 95001
  • Trenćín, Slovakia, 91171
  • Trnava, Slovakia, 917 75
  • Ľubochňa, Slovakia, 034 91
• Spain
  • Girona, Spain, 17007
  • Lleida, Spain, 25198
  • Madrid, Spain, 28040
  • Madrid, Spain, 46940
  • Barcelona
    • Badalona, Barcelona, Spain, 08916
  • Gipuzkoa
    • San Sebastian, Gipuzkoa, Spain, 20014
  • Madrid
    • Alcorcon, Madrid, Spain, 23922
  • Valencia
    • Manises, Valencia, Spain, 46940
• Sweden
  • Linköping, Sweden, 58185
  • Lund, Sweden, 22185
  • Stockholm, Sweden, 17176
• United Kingdom
  • Bradford, United Kingdom, BD96RJ
  • Bristol, United Kingdom, BS10 5NB
  • Burton on Trent, United Kingdom, DE13 0RB
  • Coventry, United Kingdom, CV22DX
  • Derby, United Kingdom, DE22 3NE
  • Edinburgh, United Kingdom, EH16 4SA
  • Lancaster, United Kingdom, LA1 4RP
  • Liverpool, United Kingdom, L7 8XP
  • London, United Kingdom, NW3 2QG
  • Manchester, United Kingdom, M23 9LT
  • Merthyr, United Kingdom, CF47 9DT
  • Stoke-on-Trent, United Kingdom, ST4 6QG
• United States
  • Alabama
    • Anniston, Alabama, United States, 36207
  • Nevada
    • Las Vegas, Nevada, United States, 89109

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

• Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria.
• Has at least 1 skin ulcer located on or below the malleolus that presents with the following clinical manifestations of a moderate or severe infection based on the Infectious Disease Society of America guidelines for the "Diagnosis and Treatment of Diabetic Foot Infections" (CID 2012; 54:132-173) (IDSA guidelines):
• has ≥ 2 manifestations of inflammation (local swelling or induration, erythema, local tenderness or pain, local warmth, purulent discharge (thick, opaque to white or sanguineous secretion)
• has ≥ 1 of the following characteristics: erythema > 2cm, or involving structures deeper than skin and subcutaneous tissues (e.g. abscess, osteomyelitis, septic arthritis, fasciitis) For patients with multiple infected ulcers, the ulcer with the highest Diabetic Foot Infection Wound score (DFI score) must be on or below the malleolus and all infected ulcers must be completely coverable using no more than 4 sponges (sponges cannot be cut).
• Has documented adequate arterial perfusion in the affected limb(s) (either palpable dorsalis pedis and posterior tibial pulses, or normal Doppler wave forms, a toe blood pressure ≥ 45 mm Hg or participation is approved by a vascular surgeon)
• Has received appropriate surgical intervention to remove all necrotic and infected bone if diagnosed with osteomyelitis.
• Has received appropriate surgical debridement to remove all gangrenous tissue.

Exclusion Criteria:

Has a known history of hypersensitivity to gentamicin (or other aminoglycosides).

• Has a known or suspected hypersensitivity to bovine collagen.
• Has an ulcer infection which, based upon the patient's known history of hypersensitivity and/or as otherwise in the opinion of the investigator, cannot be adequately treated with at least one of the empiric systemic antibiotic regimens allowed by this protocol.
• Has an ulcer associated with prosthetic material or an implanted device.
• Has received any systemic or topical antibiotic therapy for any reason within 7 days of randomization unless it was administered to specifically treat the infected ulcer(s) and only within 36 hours of randomization.
• Requires or is likely to require treatment with any concomitant topical product or wound therapy before the first follow-up study visit.
• Is severely immunocompromised, or likely to become severely immunocompromised during the study, in the opinion of the investigator.
• Has a history of myasthenia gravis or other neurological condition where gentamicin use is contraindicated as determined by the investigator.
• Has a history of epilepsy.
• Has a history of alcohol or substance abuse in the past 12 months.
• Has an uncontrolled illness that, in the opinion of the investigator, is likely to cause the patient to be withdrawn from the trial or would otherwise interfere with interpreting the results of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Gentamicin sponge group; Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.	Drug: Gentamicin Collagen sponge; Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base); Other Names: Cogenzia
Placebo Comparator: Placebo sponge group; Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.	Other: Placebo; Matching placebo sponge
No Intervention: No sponge group; Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection)	The primary efficacy variable is the percent of patients with a clinical outcome of clinical cure (Resolution of all clinical signs and symptoms of infection) at F/U visit 1	approximately 10 days after end of treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients With Re-infections		up to 90 days after treatment stopped
Time to Clinical Response	Time in Days to Clinical Cure	up to 90 days after treatment stopped
Percent of Subjects That Had an Amputation Associated With the Target Ulcer	Modified Intent-to-Treat Population - Percent of subjects that had an amputation associated with the target ulcer	up to 90 days after treatment stopped

Collaborators and Investigators

• Sponsor: Innocoll

Study record dates

Study Major Dates

• Study Start: June 1, 2015
• Primary Completion (Actual): September 1, 2016
• Study Completion (Actual): September 1, 2016

Study Registration Dates

• First Submitted: May 14, 2015
• First Submitted That Met QC Criteria: May 15, 2015
• First Posted (Estimate): May 18, 2015

Study Record Updates

• Last Update Posted (Actual): September 29, 2021
• Last Update Submitted That Met QC Criteria: September 2, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Skin Diseases; Endocrine System Diseases; Diabetic Angiopathies; Leg Ulcer; Skin Ulcer; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies; Foot Diseases; Diabetic Foot; Foot Ulcer; Ulcer; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Anti-Bacterial Agents; Protein Synthesis Inhibitors; Gentamicins
• Other Study ID Numbers: INN-TOP-005